Dr. Clarke is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Dumc
Box 3951
Durham, NC 27710Phone+1 317-670-7833
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2011 - 2014- Duke University HospitalResidency, Internal Medicine, 2008 - 2011
Indiana University School of MedicineClass of 2008
Certifications & Licensure
NC State Medical License 2008 - 2025
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902) Start of enrollment: 2020 Jun 09
Publications & Presentations
PubMed
- Identifying predictors of spatiotemporal variations in residential radon concentrations across North Carolina using machine learning analytics.Zhenchun Yang, Lauren Prox, Clare Meernik, Yadurshini Raveendran, David J Press
Environmental Pollution. 2025-02-15 - Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated...Jacob M Sands, Stéphane Champiat, Horst-Dieter Hummel, Kelly G Paulson, Hossein Borghaei
Cancer. 2025-02-01 - 1 citationsComplement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.Jeffrey M Clarke, George R Simon, Hirva Mamdani, Lin Gu, James E Herndon 2nd
Nature Communications. 2025-01-02
Lectures
- Real-world (rw) clinical outcomes for advanced/metastatic non-small cell lung cancer (aNSCLC) patients (pts) treated with second line (2L) ramucirumab plus docetaxel (...2019 ASCO Annual Meeting - 6/1/2019
- Real-world tumor response (rwTR) to ramucirumab plus docetaxel (R+D) post platinum-based (Pt) and immune checkpoint inhibitor (ICI) therapy in advanced non-small cell ...2019 ASCO Annual Meeting - 6/1/2019
- Veliparib in combination with nivolumab and platinum doublet chemotherapy (CT) in metastatic/advanced NSCLC.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
Poziotinib Shows Promise in Hard-to-Treat NSCLC Exon 20 MutationsNovember 7th, 2019
Spectrum Announces Expansion of the Poziotinib Clinical ProgramJuly 22nd, 2019- OncLive® Presents State of the Science Summit™ on Non-Small Cell Lung CancerMay 8th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
